Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 32 Issue 1, January 2014

Soybean aphid nymphs (Aphis glycines) navigating trichomes on the underside of a soybean leaf. Bonning et al. use a plant virus coat protein to deliver an insect-specific neurotoxin from the aphid gut into the body cavity, providing a new strategy for managing sap-sucking agricultural pests (p 102). Credit: Greg VanNostrand

Editorial

  • The US Food and Drug Administration (FDA) must clarify how it intends to enforce device regulation on direct-to-consumer (DTC) services that offer to interpret genome variation.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

News Feature

  • A growing market for therapeutic drugs to treat pets is fostering a startup boom. Gunjan Sinha reports.

    • Gunjan Sinha
    News Feature
Top of page ⤴

Bioentrepreneur

  • Fundraising is an integral part of almost every young biotech's business strategy, yet many entrepreneurs do not have a systematic approach for identifying and prioritizing potential investors—many of whom work outside of traditional venture capital.

    • Dennis Ford
    • Barbara Nelsen
    Bioentrepreneur
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • Regulatory fallout from a scandal surrounding the fabrication of data used to support a molecular test in a Duke University cancer trial is exacting an unjustifiable toll not only on health economics but also on patient lives.

    • Razelle Kurzrock
    • Hagop Kantarjian
    • David J Stewart
    Commentary
Top of page ⤴

Feature

  • Biologics sales grew at an incredible rate during the past 18 months, especially when compared with pharmaceuticals. But with pressure on pricing and biosimilars looming, how long will it be until biologics' last hurrah?

    • Saurabh (Rob) Aggarwal
    Feature
  • Compared with other US public-sector research institutions, the US National Institutes of Health has contributed inventions that have had a disproportionately greater impact on the overall number of products produced, drugs granted orphan status and drugs granted priority review.

    • Sabarni K Chatterjee
    • Mark L Rohrbaugh
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • Transient treatment of diabetic mice with two cytokines induces acinar-to-beta-cell conversion to an extent sufficient to durably restore normoglycemia.

    • Hannah N Worchel
    • Mark A Magnuson
    News & Views
  • Fusion of a viral coat protein to an insect-specific neurotoxin delivers the molecule into aphids where it is insecticidal.

    • Anna E Whitfield
    • Dorith Rotenberg
    • Thomas L German
    News & Views
  • Wiser use of antibiotics could help combat the emergence of drug-resistant pathogens.

    • Robert E W Hancock
    News & Views
Top of page ⤴

Analysis

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Careers and Recruitment

  • Systematic attention is required to confront the challenges faced by life scientists in interdisciplinary professions in India.

    • Gayatri Saberwal
    Careers and Recruitment
  • Careers and Recruitment
Top of page ⤴

Search

Quick links